Pharmaceutical Products is ranked #9 of 49 industries by 3-month relative strength, with +9.40% excess return vs the S&P 500 over the last 63 trading days. It sits inside the Healthcare GICS sector and contains 680 stocks.
Strong climber
This group traded 1.0× its typical dollar-volume today and accounted for 4.3% of total market dollar-volume — a read on how much participation is concentrated here right now.
Strength is spread across many constituents. Healthier rotation; setups likely available beyond the obvious names.
24 of 315 constituents are within 2% of a 52-week high.
A wide move (most names above their MAs) is healthier than a narrow one led by a handful of mega-caps.
Pharmaceutical and biological manufacturers — medicinal chemicals, drug preparations, in-vitro diagnostics, and biological products (SIC 2830–2836).
Pharmaceutical Products is one of 49 industries in the Fama-French taxonomy. SIC code-based classification published monthly by Ken French at Dartmouth. The FF49 groupings are intentionally coarser than GICS or SIC alone — useful for market-rotation reads, less useful for fine-grained screening.
FF49 is intentionally coarse — useful for rotation reads, less useful for fine-grained screening. Read the methodology →
As of Jul 6, 2026, the pharmaceutical products industry is ranked #9 of 49by 3-month relative strength versus the S&P 500. It is currently outperforming the market, with an excess return of +9.40% over the past 63 trading days.
The 1-month rank is #3, the 6-month rank is #10, and the 1-year rank is #3. Compare these to spot a rotation: a falling 6M rank with a rising 1M rank tells you the industry is turning — money is starting to come back.
The 680 constituents are ranked by relative strength above. See the full constituents table for per-name RS.
How many stocks are in the Pharmaceutical Products industry?
680 US-listed core stocks (common shares + ADRs) map to the Pharmaceutical Products Fama-French industry as of 2026-07-06.
What GICS sector does Pharmaceutical Products belong to?
Pharmaceutical Products maps to the Healthcare GICS sector.
How is relative strength computed?
Each constituent’s excess log-return versus the S&P 500 over the window, aggregated market-cap-weighted across the industry. Industries above zero are outpacing the broad market; below zero are lagging.